We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medicines Company's Key Drugs Set for Growth in 2017?
Read MoreHide Full Article
On Jul 7, 2017, we issued an updated report on The Medicines Company .
The Medicines Co. is a global biopharmaceutical company, focused on advancing the treatment of critical care patients through delivery of innovative, cost-effective medicines to the worldwide hospital marketplace.
The Medicines Co.’s shares have outperformed the Zacks classified Medical-Biomed/Genetics industry so far this year. The company’s shares have surged 12.9% compared with the industry’s register of 7% increase.
The company’s portfolio is marked with four marketed products namely, Angiomax, Ionsys, Minocin and Orbactiv.
With the company’s flagship product, Angiomax (an anticoagulant in patients undergoing coronary angioplasty), facing generic competition in the U.S, the company’s focus lies on its pipeline candidates. It has two pipeline candidates with blockbuster potential: Inclisiran and Carbavance.
Inclisiran is a PCSK9 inhibitor, currently being evaluated in a phase II ORION study for treating patient with hypercholesterolemia. Note that The Medicines Co. is developing Inclisiran in partnership with Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) .
In Apr 2017, both companies had announced that the FDA has approved plans on phase III study design for Inclisiran, which in turn will support the submission of a New Drug Application (NDA).
On the other hand, Carbavance was evaluated in a phase III study for treating patients with urinary tract infections. In Feb 2017, the FDA had granted a priority review of the new drug application (NDA) filing for Carbavance. The approval of the drug is expected in the second half of 2017 in the U.S.
Successful development and commercialization of these candidates will further boost the company’s top line, considering the lucrative markets they are targeting.
The Medicines Co. has also undertaken a restructuring program to enhance shareholder value. The company is exploring options for optimizing the capital structure and liquidity position by divesting certain non-core products.
In Jun 2016, the company had divested its non-core cardiovascular assets such as, Cleviprex and Kengreal. It has also divested another drug from cardiovascular portfolio called Argatroban to the Italian pharmaceutical company, Chiesi, for $264 million in cash as well as potential sales-based milestone payments of up to $480 million.
The above-mentioned steps have allowed the company to focus on core assets and also provide it with a source of non-dilutive funds.
While The Medicines Co.’s pipeline candidates are being developed for therapeutic areas with blockbuster potential, some of these markets are highly competitive. The PCSK9 inhibitor market has two players – Amgen’s (AMGN - Free Report) Repatha and Regeneron/Sanofi’s (SNY - Free Report) Praluent.
The market is also challenging with players looking for explicit evidence of outcomes improvement and demanding significant discounts, particularly at the beginning of product lifecycles.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Are Medicines Company's Key Drugs Set for Growth in 2017?
On Jul 7, 2017, we issued an updated report on The Medicines Company .
The Medicines Co. is a global biopharmaceutical company, focused on advancing the treatment of critical care patients through delivery of innovative, cost-effective medicines to the worldwide hospital marketplace.
The Medicines Co.’s shares have outperformed the Zacks classified Medical-Biomed/Genetics industry so far this year. The company’s shares have surged 12.9% compared with the industry’s register of 7% increase.
The company’s portfolio is marked with four marketed products namely, Angiomax, Ionsys, Minocin and Orbactiv.
With the company’s flagship product, Angiomax (an anticoagulant in patients undergoing coronary angioplasty), facing generic competition in the U.S, the company’s focus lies on its pipeline candidates. It has two pipeline candidates with blockbuster potential: Inclisiran and Carbavance.
Inclisiran is a PCSK9 inhibitor, currently being evaluated in a phase II ORION study for treating patient with hypercholesterolemia. Note that The Medicines Co. is developing Inclisiran in partnership with Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) .
In Apr 2017, both companies had announced that the FDA has approved plans on phase III study design for Inclisiran, which in turn will support the submission of a New Drug Application (NDA).
On the other hand, Carbavance was evaluated in a phase III study for treating patients with urinary tract infections. In Feb 2017, the FDA had granted a priority review of the new drug application (NDA) filing for Carbavance. The approval of the drug is expected in the second half of 2017 in the U.S.
Successful development and commercialization of these candidates will further boost the company’s top line, considering the lucrative markets they are targeting.
The Medicines Co. has also undertaken a restructuring program to enhance shareholder value. The company is exploring options for optimizing the capital structure and liquidity position by divesting certain non-core products.
In Jun 2016, the company had divested its non-core cardiovascular assets such as, Cleviprex and Kengreal. It has also divested another drug from cardiovascular portfolio called Argatroban to the Italian pharmaceutical company, Chiesi, for $264 million in cash as well as potential sales-based milestone payments of up to $480 million.
The above-mentioned steps have allowed the company to focus on core assets and also provide it with a source of non-dilutive funds.
While The Medicines Co.’s pipeline candidates are being developed for therapeutic areas with blockbuster potential, some of these markets are highly competitive. The PCSK9 inhibitor market has two players – Amgen’s (AMGN - Free Report) Repatha and Regeneron/Sanofi’s (SNY - Free Report) Praluent.
The market is also challenging with players looking for explicit evidence of outcomes improvement and demanding significant discounts, particularly at the beginning of product lifecycles.
The Medicines Company Price and Consensus
The Medicines Company Price and Consensus | The Medicines Company Quote
Zacks Rank
The Medicines Co. currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>